Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Other Non-Current Liabilities (2021 - 2026)

Mesoblast (MESO) posted Other Non-Current Liabilities of $14.2 million for Q4 2025, up 147.59% sequentially from $5.7 million in Q2 2025, and down 48.59% YoY from $27.6 million in Q4 2024.

Analysis

Mesoblast (MESO) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

Mesoblast has reported Other Non-Current Liabilities for 11 years, with the latest figure at $14.2 million in Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 48.59% year-over-year to $14.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.2 million (down 48.59% YoY) and the FY2025 annual result came in at $5.7 million, up 23.18% from the prior year.
  • Other Non-Current Liabilities climbed to $14.2 million in Q4 2025 per MESO's latest filing, from $5.7 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $27.6 million in Q4 2024 and troughed at $2.2 million in Q2 2022.
  • A 5-year average of $15.2 million and a median of $17.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities jumped 148.33% in 2023, then slumped 48.59% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $22.3 million in 2021, then declined by 19.9% to $17.9 million in 2022, then dropped by 4.37% to $17.1 million in 2023, then surged by 61.47% to $27.6 million in 2024, then plunged by 48.59% to $14.2 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.2 million, $5.7 million, and $27.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Mesoblast 2.24 Bn 2.14 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8.91 Mn
Dec 31, 2025 14.17 Mn
Jun 30, 2025 5.72 Mn
Dec 31, 2024 13.44 Mn
Jun 30, 2024 4.65 Mn
Dec 31, 2023 992,000.00
Jun 30, 2023 5.43 Mn
Mar 31, 2023 4.45 Mn
Dec 31, 2022 3.93 Mn
Sep 30, 2022 2.59 Mn
Jun 30, 2022 2.19 Mn
Mar 31, 2022 5.03 Mn
Dec 31, 2021 6.06 Mn